Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.120 +0.050 (+1.23%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Can This Beaten-Down AI Stock Bounce Back in 2026? ↗

January 28, 2026

It might take a while for this AI company to prove its worth, if it ever does so.

Via The Motley Fool

Topics Artificial Intelligence

2 AI Stocks to Buy in 2026, and 1 to Avoid ↗

January 16, 2026

Some AI-focused companies are not worth the trouble.

Via The Motley Fool

Topics Artificial Intelligence

Beyond the Protein: How AlphaFold 3 Redefined the Blueprint of Life and Accelerated the Drug Discovery Revolution

January 12, 2026

In the two years since its unveiling, AlphaFold 3 (AF3) has fundamentally transformed the landscape of biological research, moving the industry from simple protein folding to a comprehensive "all-atom"...

Via TokenRing AI

Topics Artificial Intelligence

From Silicon to Syringes: Nvidia’s AI Dominance Solidified Through Landmark Eli Lilly Alliance

January 12, 2026

In a move that signals the definitive convergence of high-performance computing and biotechnology, NVIDIA Corporation (NASDAQ: NVDA) and Eli Lilly and Company (NYSE: LLY) announced a massive $1 billion...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

January 06, 2026

From Recursion Pharmaceuticals

Via GlobeNewswire

The $3 Billion Bet: How Isomorphic Labs is Rewriting the Rules of Drug Discovery with Eli Lilly and Novartis

January 01, 2026

In a move that has fundamentally reshaped the landscape of the pharmaceutical industry, Isomorphic Labs—the London-based drug discovery arm of Alphabet Inc. (NASDAQ: GOOGL)—has solidified its position...

Via TokenRing AI

Topics Artificial Intelligence

The Great Unlocking: How AlphaFold 3’s Open-Source Pivot Sparked a New Era of Drug Discovery

January 01, 2026

The landscape of biological science underwent a seismic shift in November 2024, when Google DeepMind, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), officially released the source code and model...

Via TokenRing AI

Topics Artificial Intelligence

Forget Recursion Pharmaceuticals Stock. This Is a Much Better Buy. ↗

January 01, 2026

These two companies have very different risk-reward profiles.

Via The Motley Fool

Topics Artificial Intelligence

Cathie Wood’s Strategic Pivot: Ark Invest Trims Tesla Holdings to Fuel AI and Crypto Bets Ahead of 2026

December 25, 2025

In a move that has captured the attention of Wall Street as the year draws to a close, Cathie Wood’s Ark Invest has executed a series of significant sales of Tesla, Inc. (NASDAQ: TSLA) stock throughout...

Via MarketMinute

Topics Artificial Intelligence ETFs Economy

Myseum (NASDAQ: MYSE) Ignites “Picture Party,” a New Era in Social Media on All Apple (NASDAQ: AAPL) Devices Now! more stocks inside…

December 17, 2025

Via AB Newswire

Topics Artificial Intelligence

Why Recursion Pharmaceuticals Stock Vaulted 11% Higher on Wednesday ↗

December 17, 2025

Sentiment on the company has improved following solid clinical trial results from one of its pipeline drugs earlier this month.

Via The Motley Fool

Topics Artificial Intelligence

Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why ↗

December 17, 2025

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10.

Via Benzinga

Oracle, Hut 8, Processa Pharmaceuticals, Recursion Pharmaceuticals, Udemy: Stocks Making The Biggest Moves Today ↗

December 17, 2025

Oracle shares were down over 5% in Wednesday’s midday session after Blue Owl Capital reportedly withdrew from a $10 billion investment in the company’s new facility in Saline Township, Michigan.

Via Stocktwits

Topics Artificial Intelligence ETFs Stocks

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks

December 08, 2025

From Recursion Pharmaceuticals, Inc.

Via GlobeNewswire

Jim Cramer: This Health Care Stock Has Been 'Horrendous' ↗

December 05, 2025

Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and CEO transition. Stock has mixed technicals and death cross.

Via Benzinga

10 AI Stocks Worth Buying Right Now ↗

December 04, 2025

Building an artificial intelligence (AI) portfolio means looking beyond the obvious megacap names.

Via The Motley Fool

Topics Artificial Intelligence

Global Prescription Drug Market Poised for Trillion-Dollar Surge by 2035

December 03, 2025

The global prescription drugs market is on the cusp of a significant expansion, with recent market reviews and forecasts projecting a robust growth trajectory through 2035. This anticipated surge,...

Via MarketMinute

Topics Artificial Intelligence Death Intellectual Property

Beyond the Hype: AI’s Quiet Revolution in Niche Sectors Reshapes Industries from Medicine to Agriculture

December 01, 2025

Artificial intelligence, often spotlighted for its advancements in mainstream applications like conversational agents and autonomous vehicles, is quietly orchestrating a profound transformation across...

Via TokenRing AI

Topics Artificial Intelligence Economy Emissions

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025

December 01, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

popEVE AI: Harvard-Developed Model Set to Revolutionize Rare Disease Diagnosis and Drug Discovery

November 25, 2025

Cambridge, MA & Barcelona, Spain – November 25, 2025 – A groundbreaking artificial intelligence model, popEVE, developed by a collaborative team of researchers from Harvard Medical School and the...

Via TokenRing AI

Topics Artificial Intelligence

Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? ↗

November 24, 2025

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company.

Via The Motley Fool

Topics Artificial Intelligence

Is Recursion Pharmaceuticals a Meme Stock? ↗

November 19, 2025

The answer seems straightforward enough.

Via The Motley Fool

Topics Artificial Intelligence

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

From MarketNewsUpdates.com

Via GlobeNewswire

Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025

November 14, 2025

The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Longevity-Focused Health Fueling U.S. Anti-Aging Products Market Projected to Reach $27 Billion By 2033

November 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:NTLA),(NASDAQ:ZYME),(NYSE:ANVS) EQNX::TICKER_END

Via FinancialNewsMedia

Forget Recursion Pharmaceuticals: This Could Be an Even Better Artificial Intelligence (AI) Stock ↗

November 12, 2025

Recursion is about to go toe-to-toe with the largest healthcare company.

Via The Motley Fool

Topics Animal Testing Artificial Intelligence

AI Unlocks Gene-Editing Revolution: $2 Million Grant Propels Disease Cures

November 06, 2025

A groundbreaking $2 million grant from the National Institutes of Health (NIH) is set to dramatically accelerate advancements in gene-editing technology, with artificial intelligence (AI) emerging as...

Via TokenRing AI

Topics Artificial Intelligence Climate Change Intellectual Property

Nvidia's AI Reign: A $5 Trillion Bellwether Shaping Wall Street's Fortunes

November 11, 2025

Nvidia's (NASDAQ: NVDA) recent stock performance has been a whirlwind of soaring highs and sharp corrections, acting as a potent barometer for the broader Wall Street landscape as of November 11, 2025....

Via MarketMinute

Topics Artificial Intelligence Economy Law Enforcement

Recursion Pharmaceuticals (NASDAQ:RXRX) Reports Q3 2025 Results with Revenue Miss and Extended Cash Runway ↗

November 05, 2025

Recursion's Q3 2025 results show a major revenue miss and widening loss, but the company highlights strong partnerships and a cash runway into 2027.

Via Chartmill

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

November 05, 2025

From Recursion Pharmaceuticals

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.